81P Is PD-1 inhibitor based treatment better than chemotherapy for metastatic NSCLC patients with PD-L1≥50% who develop EGFR-TKI resistance? A real-world investigation. (December 2022) - Li, Y.; Jiang, H.; Qian, F.; Cheng, Y.; Zhang, Y.; Lu, J.; Lou, Y.; Han, B.; Zhang, W.